Document |
Document Title |
WO/2023/227882A1 |
The present invention relates to the compound 4-(6-oxo-2-(trifluoromethyl)-3,6- dihydrochromeno[7,8-d]imidazol-8- yl)benzonitrile, also known as CF3CN, for use in the treatment of diseases and conditions associated with movement disorder.
|
WO/2023/226789A1 |
Provided are a functionalized targeting formulation, a method for preparing same, and a use thereof. The functionalized targeting formulation comprises an amphiphilic polymer and a biological agent. The amphiphilic polymer comprises a mo...
|
WO/2023/226965A1 |
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as ROCK inhibitors. Also disclosed are pharmaceutical compositions comprising a compound of Formula (I), and methods of using s...
|
WO/2023/228701A1 |
The present invention provides a preventive agent, disease progression inhibitor, or therapeutic agent for central demyelinating diseases, comprising a FFAR1 receptor agonist.
|
WO/2023/227867A1 |
The present invention provides compounds of formula (I): 5 A 1 X Y N R 2 R 1 A 2 A 3 A 4 n Formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1, R2, n, A1, A2, A3, A4, X and Y are as defined in the...
|
WO/2023/226171A1 |
A cod skin collagen peptide-loaded trimethyl chitosan nanoparticle and the use thereof. A method for preparing the cod skin collagen peptide-loaded trimethyl chitosan nanoparticle, wherein the method comprises: adding an aqueous solution...
|
WO/2023/228994A1 |
The present disclosure addresses the problem of providing at least a technology for enhancing the expression of SIRT3 genes. Said problem is solved by a composition for enhancing SIRT3 gene expression, the composition containing urolithi...
|
WO/2023/229040A1 |
In the description of the present invention, provided is an antisense oligonucleotide, or a pharmaceutically acceptable salt thereof, which comprises 15-22 nucleotides, and which is complementary to a nucleic acid including at least 15 c...
|
WO/2023/226614A1 |
Disclosed is use of N-(pyridin-2-yl)pyridine-2-thioamide represented by the following formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an anti-hypoxic medicament, for treating or preventing diseases caused ...
|
WO/2023/229443A1 |
The present invention relates to a novel peptide and use thereof. More specifically, the present invention provides: a novel peptide in which 1 to 4 amino acids, from among amino acids excluding glycine, are L-type amino acids and the re...
|
WO/2023/230543A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
WO/2023/227697A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
WO/2023/225773A1 |
Solid forms of mesembrine are provided, along with related methods of manufacture. The solid form compositions are useful, for example, in the preparation of pharmaceutical compositions.
|
WO/2023/230303A1 |
The present invention relates to the use of entheogens to reduce or ameliorate cognitive decline related to anesthesia or sedation or increase the resilience of patients to the stresses of surgery including physical and psychological seq...
|
WO/2023/230099A1 |
Provided herein are compounds comprising an oligonucleotide molecule conjugated to a ligand for a glucose transporter (GLUT) for modulation of a target molecule, compositions comprising the same, and methods of using the compositions.
|
WO/2023/227698A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
WO/2023/230513A1 |
Provided are a Lactobacillus plantarum strain, Lactobacillus plantarum PDA6, and a composition thereof. Also provided are methods using Lactobacillus plantarum PDA6 or a composition thereof for treating anxiety disorder or depression.
|
WO/2023/228204A1 |
The present disclosure provides methods for treating Alzheimer's disease (AD) comprising administering clomipramine or a pharmaceutically acceptable salt thereof. The administration of clomipramine increases the levels of TAp73 and decre...
|
WO/2023/225728A1 |
The invention is intended for the health sector and comprises a biodegradable resorbable subcutaneous implant formed by 10 to 1000 mg essential oil extracted from Cannabis sativa and/or Cannabis indica (full or broad spectrum), 10 to 500...
|
WO/2023/229819A1 |
The present disclosure is directed to methods of producing oligodendrocyte progenitor cells (OPCs). In addition, methods of treating demyelinating diseases using oligodendrocyte progenitor cells (OPCs) are also disclosed.
|
WO/2023/222051A1 |
Provided in the present invention is the use of a macrophage migration inhibitory factor (MIF), RIPK1, an MIF inhibitor and an RIPK1 inhibitor in perioperative ischemic brain injuries. The present invention discloses the key functions of...
|
WO/2023/224979A1 |
This disclosure relates to novel modified oligonucleotides with increased stability and extended in vivo mRNA silencing activity.
|
WO/2023/225620A1 |
The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting...
|
WO/2023/225635A1 |
Provided herein are methods of improving mood and/or ameliorating a depressive symptom, treating or preventing a psychiatric or neurologic disorder, and/or enhancing the beneficial effects of physical activity in a subject by administeri...
|
WO/2023/224134A1 |
Disclosed in the present invention is a composition for improving cognitive ability using water soluble curcumin and boswellia extracts.
|
WO/2023/225041A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
|
WO/2023/223057A1 |
The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in...
|
WO/2023/224995A1 |
Provided herein are methods and compositions for treating a neurodegenerative disease (e.g., ALS). The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.
|
WO/2023/222703A1 |
The present invention relates to use of a composition comprising an effective amount of a combination of fisetin and/or derivative thereof and quercetin and/or derivative for maintenance of joint health or prevention or treatment of join...
|
WO/2023/225021A1 |
In various aspects and embodiments provided are compositions and methods for treating a patient that has ALS (or Lou Gehrig's disease or motor neuron disease). More specifically, the disclosure in some embodiments includes administration...
|
WO/2023/222702A1 |
Composition comprising a combination of oleuropein or metabolite thereof and fisetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional su...
|
WO/2023/224431A1 |
The present invention relates to a pharmaceutical composition comprising, as an active ingredient, hypothalamus-like organoid-derived neural stem cells for preventing and treating geriatric diseases. It was found that decreased memory, c...
|
WO/2023/224989A1 |
The present disclosure provides compounds, compositions, and/or methods for treating, preventing, inhibiting, ameliorating, or delaying the onset of Huntington's disease and/or a HTT proteinopathy in a subject. The methods can comprise a...
|
WO/2023/224372A1 |
The present invention relates to a Prevotella histicola strain useful for the prevention or treatment of sleep disorders. Prevotella histicola exhibits an increase in total sleep time, non-REM (NREM) sleep time and REM sleep time, and a ...
|
WO/2023/222705A1 |
Composition comprising a combination of fisetin or derivative thereof and quercetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional sup...
|
WO/2023/224604A1 |
The present invention primarily relates to the use of a fragrance composition for conveying a positive mood in a subject, preferably a human, as well as to the use of a product containing the fragrance composition. Furthermore, the prese...
|
WO/2023/225596A1 |
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and...
|
WO/2023/223172A1 |
Provided are compositions comprising terpene mixtures consisting of 1000-4500 ppm myrcene, 1000-4000 ppm terpineol, 1000-5500 ppm caryophyllene and 1000-45000 ppm nerolidol; 1000-4500 ppm alpha-pinene, 1000-4000 ppm sabinene, 1000-4000 p...
|
WO/2023/225511A1 |
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2...
|
WO/2023/224833A1 |
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications re...
|
WO/2023/222871A1 |
The present invention relates to proteins and polypeptides from the salivary gland of Ixodes ricinus for their use for preventing and/or treating brain inflammation and diseases or conditions associated with brain inflammation, and metho...
|
WO/2023/225125A1 |
A method of monitoring and treating a subject with ALS based on biomarkers. In some embodiments, the method comprises: identifying that a subject has a ratio of LPS1EGF associated with ALS; and based on the identifying that the subject h...
|
WO/2023/222924A1 |
The present invention concerns Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or...
|
WO/2023/225640A2 |
Epilepsy is one of the most common neurological disorders. However, there are currently no drugs available to prevent and/or reduce the development of said disorder. Thus, compositions and methods described herein prevent and/or arrest t...
|
WO/2023/222124A1 |
Disclosed in the present invention are a 5,6-dihydro-1,2,4-triazine compound and the pharmaceutical use thereof as a GLP-1 receptor agonist. A structure of the 5,6-dihydro-1,2,4-triazine compound is represented by formula (I), and in the...
|
WO/2023/221814A1 |
Disclosed is a long-acting sustained-release preparation pharmaceutical composition containing pramipexole, comprising a pharmaceutically acceptable salt of pramipexole and a pharmaceutical high polymer material. The preparation is selec...
|
WO/2023/225190A1 |
Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering from the disease at least one Retinoid X receptor gamma (RXRy) agonist and at least o...
|
WO/2023/222080A1 |
A pharmaceutical composition is provided. The pharmaceutical composition comprises an active pharmaceutical ingredient (API), a polymer and a solvent. The API comprsises cariprazine, a pharmaceutically acceptable salt of cariprazine, or ...
|
WO/2023/225244A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
|
WO/2023/222005A1 |
The present invention belongs to the technical field of medicines, and relates to a class of aromatic heterocyclic compounds serving as an LRRK2 inhibitor. The present invention provides a class of compounds with a novel structure, which...
|